591 related articles for article (PubMed ID: 32521132)
1. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E;
Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041
[TBL] [Abstract][Full Text] [Related]
4. Givosiran: A Review in Acute Hepatic Porphyria.
Syed YY
Drugs; 2021 May; 81(7):841-848. PubMed ID: 33871817
[TBL] [Abstract][Full Text] [Related]
5. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
[TBL] [Abstract][Full Text] [Related]
6. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M
Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858
[TBL] [Abstract][Full Text] [Related]
7. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
Sardh E; Harper P
J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
[TBL] [Abstract][Full Text] [Related]
8. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
Wang B; Bonkovsky HL; Lim JK; Balwani M
Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
Kuter DJ; Bonkovsky HL; Monroy S; Ross G; Guillén-Navarro E; Cappellini MD; Minder AE; Hother-Nielsen O; Ventura P; Jia G; Sweetser MT; Thapar M;
J Hepatol; 2023 Nov; 79(5):1150-1158. PubMed ID: 37479139
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
Agarwal S; Simon AR; Goel V; Habtemariam BA; Clausen VA; Kim JB; Robbie GJ
Clin Pharmacol Ther; 2020 Jul; 108(1):63-72. PubMed ID: 31994716
[TBL] [Abstract][Full Text] [Related]
11. [Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria].
Stölzel U
Z Gastroenterol; 2020 Aug; 58(8):785. PubMed ID: 32785915
[No Abstract] [Full Text] [Related]
12. Givosiran to treat acute porphyria.
Honor A; Rudnick SR; Bonkovsky HL
Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
[TBL] [Abstract][Full Text] [Related]
13. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP).
Massachi S; Epstein J; Hurd J; Bonkovsky HL
J Med Econ; 2020 Dec; 23(12):1441-1449. PubMed ID: 33043761
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort.
Lee MJ; Kuo HC; Chou LN; Sweetser MT; Wang JD
J Formos Med Assoc; 2024 Jun; 123(6):679-686. PubMed ID: 38044204
[TBL] [Abstract][Full Text] [Related]
15. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report.
Mazzoli M; Ricci A; Vaudano AE; Marcacci M; Marchini S; Bergonzini P; Di Pierro E; Pischik E; Iughetti L; Pietrangelo A; Meletti S; Ventura P
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3268-3274. PubMed ID: 38708485
[TBL] [Abstract][Full Text] [Related]
16. Givosiran in acute intermittent porphyria: A personalized medicine approach.
Poli A; Schmitt C; Moulouel B; Mirmiran A; Talbi N; Rivière S; Cerutti D; Bouchoule I; Faivre A; Grobost V; Douillard C; Duchêne F; Fiorentino V; Dupré T; Manceau H; Peoc'h K; Puy H; Lefebvre T; Gouya L
Mol Genet Metab; 2022 Mar; 135(3):206-214. PubMed ID: 35058124
[TBL] [Abstract][Full Text] [Related]
17. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK
Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373
[TBL] [Abstract][Full Text] [Related]
18. Givosiran for the treatment of acute hepatic porphyria.
Ricci A; Ventura P
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
[TBL] [Abstract][Full Text] [Related]
19. Givosiran: First Approval.
Scott LJ
Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
To-Figueras J; Wijngaard R; García-Villoria J; Aarsand AK; Aguilera P; Deulofeu R; Brunet M; Gómez-Gómez À; Pozo OJ; Sandberg S
J Inherit Metab Dis; 2021 Jul; 44(4):961-971. PubMed ID: 33861472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
